OBJECTIVES: To determine the extent to which disease-related symptoms and impairments, which constitute measures of disease severity or targets of therapy, account for the associations between chronic diseases and universal health outcomes. DESIGN: Cross-sectional. SETTING: The Cardiovascular Health Study (CHS) and the Health, Aging and Body Composition Study (Health ABC). PARTICIPANTS: Five thousand six hundred fifty-four CHS members and 2,706 Health ABC members. MEASUREMENTS: Diseases included heart failure (HF), chronic obstructive pulmonary disease (COPD), osteoarthritis, and cognitive impairment. The universal health outcomes included self-rated health, basic and instrumental activities of daily living (ADLs and IADLs), and death. Disease-related symptoms and impairments included HF symptoms and ejection fraction (EF) for HF, Dyspnea Scale and forced expiratory volume in 1 second for COPD, joint pain for osteoarthritis, and executive function for cognitive impairment. RESULTS: The diseases were associated with the universal health outcomes (P<.001) except osteoarthritis with death (both cohorts) and cognitive impairment with self-rated health (Health ABC). Symptoms and impairments accounted for 30% or more of each disease's effect on the universal health outcomes. In CHS, for example, HF was associated with one fewer (0.918) ADL and IADL performed without difficulty than no HF; HF symptoms accounted for 27% of this effect and EF for only 5%. The hazard ratio for death with HF was 6.5 (95% confidence interval=4.7-8.9) with EF accounting for 40% and HF symptoms for only 14%. CONCLUSION: Disease-related symptoms and impairments accounted for much of the significant associations between the four chronic diseases and the universal health outcomes. Results support considering universal health outcomes as common metrics across diseases in clinical decision-making, perhaps by targeting the disease-related symptoms and impairments that contribute most strongly to the effect of the disease on the universal health outcomes.
OBJECTIVES: To determine the extent to which disease-related symptoms and impairments, which constitute measures of disease severity or targets of therapy, account for the associations between chronic diseases and universal health outcomes. DESIGN: Cross-sectional. SETTING: The Cardiovascular Health Study (CHS) and the Health, Aging and Body Composition Study (Health ABC). PARTICIPANTS: Five thousand six hundred fifty-four CHS members and 2,706 HealthABC members. MEASUREMENTS: Diseases included heart failure (HF), chronic obstructive pulmonary disease (COPD), osteoarthritis, and cognitive impairment. The universal health outcomes included self-rated health, basic and instrumental activities of daily living (ADLs and IADLs), and death. Disease-related symptoms and impairments included HF symptoms and ejection fraction (EF) for HF, Dyspnea Scale and forced expiratory volume in 1 second for COPD, joint pain for osteoarthritis, and executive function for cognitive impairment. RESULTS: The diseases were associated with the universal health outcomes (P<.001) except osteoarthritis with death (both cohorts) and cognitive impairment with self-rated health (Health ABC). Symptoms and impairments accounted for 30% or more of each disease's effect on the universal health outcomes. In CHS, for example, HF was associated with one fewer (0.918) ADL and IADL performed without difficulty than no HF; HF symptoms accounted for 27% of this effect and EF for only 5%. The hazard ratio for death with HF was 6.5 (95% confidence interval=4.7-8.9) with EF accounting for 40% and HF symptoms for only 14%. CONCLUSION: Disease-related symptoms and impairments accounted for much of the significant associations between the four chronic diseases and the universal health outcomes. Results support considering universal health outcomes as common metrics across diseases in clinical decision-making, perhaps by targeting the disease-related symptoms and impairments that contribute most strongly to the effect of the disease on the universal health outcomes.
Authors: Mathew S Maurer; Daniel Burkhoff; Linda P Fried; John Gottdiener; Donald L King; Dalane W Kitzman Journal: J Am Coll Cardiol Date: 2007-02-20 Impact factor: 24.094
Authors: Laura B Herpel; Richard E Kanner; Shing M Lee; Henry E Fessler; Frank C Sciurba; John E Connett; Robert A Wise Journal: Am J Respir Crit Care Med Date: 2006-02-23 Impact factor: 21.405
Authors: Daniela Dobre; Cornelia H M van Jaarsveld; Mike J L deJongste; Flora M Haaijer Ruskamp; Adelita V Ranchor Journal: Pharmacoepidemiol Drug Saf Date: 2007-02 Impact factor: 2.890
Authors: Deborah A Cahn-Weiner; Sarah Tomaszewski Farias; Laura Julian; Danielle J Harvey; Joel H Kramer; Bruce R Reed; Dan Mungas; Margaret Wetzel; Helena Chui Journal: J Int Neuropsychol Soc Date: 2007-05-18 Impact factor: 2.892
Authors: Mary E Tinetti; Gail J McAvay; Sandy S Chang; Anne B Newman; Annette L Fitzpatrick; Terri R Fried; Peter N Peduzzi Journal: J Am Geriatr Soc Date: 2011-08-30 Impact factor: 5.562
Authors: Mieke Rijken; Nienke Bekkema; Pauline Boeckxstaens; François G Schellevis; Jan M De Maeseneer; Peter P Groenewegen Journal: Health Expect Date: 2012-06-19 Impact factor: 3.377
Authors: Emily Locke; Stephen Thielke; Paula Diehr; Anthony G Wilsdon; R Graham Barr; Nadia Hansel; Vishesh K Kapur; Jerry Krishnan; Paul Enright; Susan R Heckbert; Richard A Kronmal; Vincent S Fan Journal: COPD Date: 2013-07-02 Impact factor: 2.409
Authors: Kushang V Patel; Barbara B Cochrane; Dennis C Turk; Lori A Bastian; Sally G Haskell; Nancy F Woods; Oleg Zaslavsky; Robert B Wallace; Robert D Kerns Journal: Gerontologist Date: 2016-02
Authors: Vincent S Fan; Emily R Locke; Paula Diehr; Anthony Wilsdon; Paul Enright; Sachin Yende; Mark Avdalovic; Graham Barr; Vishesh K Kapur; Rachel Thomas; Jerry A Krishnan; Gina Lovasi; Stephen Thielke Journal: Respiration Date: 2014-09-09 Impact factor: 3.580